| Literature DB >> 31380363 |
David Wu1, Konstantin Birukov2.
Abstract
Lungs are the most vascular part of humans, accepting the totality of cardiac output in a volume much smaller than the body itself. Due to this cardiac output, the lung microvasculature is subject to mechanical forces including shear stress and cyclic stretch that vary with the cardiac and breathing cycle. Vessels are surrounded by extracellular matrix which dictates the stiffness which endothelial cells also sense and respond to. Shear stress, stiffness, and cyclic stretch are known to influence endothelial cell state. At high shear stress, endothelial cells exhibit cell quiescence marked by low inflammatory markers and high nitric oxide synthesis, whereas at low shear stress, endothelial cells are thought to "activate" into a pro-inflammatory state and have low nitric oxide. Shear stress' profound effect on vascular phenotype is most apparent in the arterial vasculature and in the pathophysiology of vascular inflammation. To conduct the flow of blood from the right heart, the lung microvasculature must be rigid yet compliant. It turns out that excessive substrate rigidity or stiffness is important in the development of pulmonary hypertension and chronic fibrosing lung diseases via excessive cell proliferation or the endothelial-mesenchymal transition. Recently, a new body of literature has evolved that couples mechanical sensing to endothelial phenotypic changes through metabolic signaling in clinically relevant contexts such as pulmonary hypertension, lung injury syndromes, as well as fibrosis, which is the focus of this review. Stretch, like flow, has profound effect on endothelial phenotype; metabolism studies due to stretch are in their infancy.Entities:
Keywords: endothelial (dys)function; endothelial mesenchymal transition; metabolism; microvasculature; pulmonary
Year: 2019 PMID: 31380363 PMCID: PMC6658821 DOI: 10.3389/fbioe.2019.00172
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1Mechanometabolomic coupling to disease states in the lung.Vascular disease states in the lung in (A) normal, (B) acute lung injury, and (C) pulmonary hypertension. In normal states, ventilation through the alveoli and perfusion occur through nitric oxide (NO) release by the endothelium. Normal microvascular perfusion (D) induces a KLF2 high state which suppresses glycolysis and promotes mitochondrial function, leading to pyruvate-derived acetyl-CoA and acetylation of microtubules, β-catenin, and maintenance of quiescence through chromatin modification. In contrast, during acute lung injury (B), flow becomes disturbed due to microvascular dysfunction, manifest by thrombosis and endothelial contraction leading to edema. Edema in the alveolus causes local hypoxia (E). Inflammation leads to glycocalyx degradation, ROS generation which, with hypoxia, activates HIF-1α. HIF-1α suppresses mitochondrial energy generation and induces glycolysis. De-acetylated microtubules release GEF-H1 for RhoA activation. Glycolysis induces NF-κB activation which can also be enhanced by β-catenin nuclear translocation, due to de-acetylation. However, hypoxia also induces HIF-2α, which inhibits β-catenin translocation. In pulmonary hypertension (C), the upstream pulmonary artery is dilated, reducing shear stress. In the microvasculature, flow is thought to be supra-normal due to thrombosis and vessel stiffness, causing endothelial damage. ECs undergo endoMT and synthesize connective tissue, which exacerbates these hemodynamical phenomena. (F) ECs in response to increased extracellular matrix stiffness stimulate YAP/TAZ activity which enhances glycolysis and anaplerosis, leading to cell proliferation and endoMT. Hypoxia pathways are also activated in pulmonary hypertension.